July 
Because syphilis infection facilitates acquisition and transmission of human immunodeficiency virus (HIV) (1, 2) , recent outbreaks of syphilis among men who have sex with men (MSM) in major U.S. cities (3), including San Francisco and Los Angeles (4, 5) , and reported increases in sexual risk behavior (5) have raised concerns about potential increases in HIV transmission. In 2002, MSM accounted for the majority of primary and secondary (P&S) syphilis cases in men reported in San Francisco (93%) and Los Angeles (81%). To investigate a potential change in HIV incidence associated with the syphilis outbreaks in the two cities, local, state, and federal health officials analyzed data from HIV counseling and testing centers and a municipal sexually transmitted disease (STD) clinic. This report describes the results of that investigation, which indicated that, as of 2002, the outbreaks of syphilis had not had a substantial impact on HIV incidence among MSM in these two cities. However, the continued increase in syphilis cases in MSM underscores the need for integrated HIV-and STD-prevention strategies to control syphilis outbreaks and prevent potential increases in HIV infections (6, 7) and for further systematic studies of HIV incidence among MSM infected with syphilis.
For this analysis, numbers and characteristics of P&S syphilis cases among MSM in San Francisco and Los Angeles were determined from STD morbidity data. Rates of P&S syphilis per 100,000 MSM were calculated for the estimated 50,782 MSM living in San Francisco in 2001 (8) . In 2002, approximately 47% and 18% of MSM with P&S syphilis in San Francisco and Los Angeles, respectively, had syphilis diagnosed at publicly funded sites, which included primarily STD clinics.
A sensitive/less sensitive HIV-1 enzyme immunoassay (EIA) (Vironostika HIV-1 Microelisa, bioMérieux, Durham, North Carolina) testing algorithm known as STARHS (9,10) was used to estimate HIV incidence by using stored blood specimens for 1) MSM receiving confidential HIV counseling and testing at the City Clinic (SFCC), San Francisco's only municipal STD clinic, and 2) MSM receiving anonymous HIV counseling and testing at University of California at San Francisco AIDS Health Project (AHP) sites. For persons tested at AHP sites (1998) (1999) (2000) (2001) (2002) and persons tested at SFCC (1998) (1999) (2000) , demographic and risk-factor information collected on the California HIV counseling and testing form was analyzed. For persons tested at SFCC (2001) (2002) , analogous information obtained from medical records was analyzed. Persons who tested reactive with the sensitive EIA and nonreactive with the less sensitive assay were considered recently HIV infected (mean seroconversion period: 170 days) (10) . Annualized HIV incidence and 95% confidence intervals (CIs) based on a normal distribution were calculated; all reported p-values were obtained by using a chi-square test for trend. In Los Angeles, data from the California and CDC HIV counseling and testing forms were used to calculate the percentages and characteristics of MSM with newly diagnosed infections. These patients had received a confidential or anonymous HIV test at publicly funded sites during 1998-2002.
San Francisco Surveillance Data
During 1998-2002, the number of P&S syphilis cases among MSM in San Francisco increased from four to 260 (Figure 1) , and the P&S syphilis rate increased from eight to 512 per 100,000 MSM. In 2002, the median age of MSM P&S syphilis patients was 38 years; 70% were white, 14% were Hispanic, and 61% were HIV-infected. P&S syphilis cases among MSM at the SFCC also increased, from four in 1998 to 106 in 2002.
MSM receiving HIV testing had similar demographic characteristics and the two San Francisco testing populations. In 2002, at AHP and SFCC, respectively, the median age of these patients was 34 and 33 years; 70% and 61% were white, 3% and 6% were black, 11% and 19% were Hispanic, 12% and 14% were Asian/Pacific Islander (A/PI), and 4% and <1% were of other race/ethnicity.
Estimated HIV incidence among MSM who were tested in San Francisco was highest in 1999 ( Figure 1 , Table 1 ) and tended to decline from 1999 to 2002 at both sites; however, the trends were not statistically significant (p = 0.13 for AHP; p = 0.36 for SFCC). When injection-drug-using MSM were excluded from analyses, HIV incidence was lower (e.g., in 2002, incidence was 2.3% [95% CI = 1.0-3.5] at AHP and 3.3% [95% CI = 1.9-4.7] at SFCC), but temporal trends in HIV incidence were similar. Median age of the 42 MSM with incident HIV infection at these testing sites in 2002 was 32 years; 23 (55%) were white, and 12 (29%) were Hispanic.
HIV incidence was estimated by STARHS for men who had P&S syphilis diagnosed at SFCC in 2002 and 2003 and who accepted confidential HIV-antibody and STARHS testing. Of 74 men, 16 (22%) were HIV seropositive, and four (25%) of these had a recent HIV infection identified by STARHS; all four of these patients reported having had HIVseronegative test results within the previous 2 years. On the basis of STARHS, estimated HIV incidence in this population was 13.9% per year (95% CI = 0.3-27.5).
Los Angeles Surveillance Data
During 2000-2002, P&S syphilis cases among MSM in Los Angeles County increased from 67 to 299, accounting for the majority of male syphilis patients ( Figure 2 ). In 2002, median age of MSM with P&S syphilis was 37 years; 51% were white, 31% were Hispanic, and 58% were HIV infected.
MSM receiving HIV testing at Los Angeles County sites had similar demographic characteristics during 1998-2002. In 2002, the median age of 15,161 MSM who were tested was 32 years; 42% were white, 10% were black, 37% were Hispanic, 7% were A/PI, and 4% were of other race/ethnicity. The percentage of MSM with HIV newly diagnosed (i.e., without any previous HIV-positive test) decreased from 4.8% (608 of 12,693) in 1998 to 4.1% (615 of 15,161) in 2002 (p<0.001) ( Table 2 ). In 2002, the 615 MSM who had newly diagnosed HIV had a median age of 32 years; 29% were white, 18% were black, and 45% were Hispanic. However, among MSM who had an HIV-negative test result within the previous 12 months, the percentage of men with a new HIVpositive test increased from 2.4% (102 of 4, 196) in 1998 to 2.9% (186 of 6,446) in 2002 (p = 0.37). The findings of this ecological analysis are subject to at least five limitations. First, whereas the overall P&S syphilis morbidity data were reported from both private and public providers, with the majority of MSM P&S syphilis cases being reported from private sources, HIV incidence (San Francisco) and new HIV diagnoses (Los Angeles) could be examined only for select populations at publicly funded HIV-testing sites. MSM attending public HIV-testing venues might differ in their demographics and risk behaviors from MSM who seek HIV testing from private providers or who have not been HIV tested. Second, changes in testing practices and number and characteristics of MSM in the two public HIV-testing populations might weaken inferences about trends in HIV incidence or new HIV diagnoses among these populations. Analyses might include persons who tested anonymously and repeatedly at SFCC, AHP, and Los Angeles HIV-testing sites, and potential changes in repeat HIV-testing patterns over time could affect HIV incidence trends. Third, the proportion of oral HIV antibody tests performed for MSM at AHP sites increased from 11% in 1998 to 36% in 2002, thus increasing the proportion of patients tested who were excluded from STARHS-based estimates of HIV incidence. Fourth, STARHS might misclassify a small percentage of persons with longstanding infection as recently infected and vice versa (9, 10) . Finally, the SFCC estimate of HIV incidence among MSM with P&S syphilis (13.9% per year) has wide associated variability (95% CI = 0.3-27.5) and must be interpreted with caution because not all male syphilis patients accepted HIV testing.
Despite the high HIV incidence in men with P&S syphilis, HIV incidence rates among MSM tested at large public sites in San Francisco and Los Angeles did not increase during 1999-2002. This stability likely is because 1) the number of new syphilis cases is small compared with the numbers of MSM at risk for HIV infection and 2) in both cities more than half of the MSM P&S syphilis patients had longstanding HIV infection before they acquired syphilis. However, if the outbreaks of syphilis continue unabated, HIV incidence among MSM at public HIV-testing sites and in the larger MSM community might increase. 
Nationwide Magnitude and Trend
During 2002, a total of 10,658 adults from 35 states were reported with BLLs >25 µg/dL ( Figure 1 ). During 2001, a total of 9,943 adults from 23 states were reported with BLLs >25 µg/dL (4) . To compare yearly totals, the numbers of adults with elevated BLLs from each state were divided by the state's annual employed population aged >16 years to determine an annual state rate (5) . The mean of the state rates in each year was then calculated to derive the average state rate. The average state rate for 2002 was 10.1 per 100,000 employed population, representing an 18% decrease from 2001 (12.3 per 100,000 employed population) ( Figure 2 ) (4). Of the 10,658 adults with BLLs >25 µg/dL in 2002, a total of 1.7 per 100,000 employed population (1, 854) were reported with BLLs >40 µg/dL, a 37% decrease compared with the 2.7 per 100,000 employed population (2,009) that were reported in 2001* (4).
Occupational Sources of Exposure
In 2002, ABLES began to collect individual data rather than summary data. These individual data for adults with BLLs >25 µg/dL included Standard Industrial Classification (SIC) codes for the industries in which they worked and information regarding nonoccupational exposures. Twenty-seven of the 35 ABLES states provided SIC codes for 6,540 adults. These 27 states reported an additional 1,257 adults for whom SIC codes were unknown or unavailable. By industrial sector, among the 6,540 adults, 58% (3,771) were exposed in the manufacturing industry; 22% (1, 458) 
Nonoccupational Sources of Exposure
The same 27 states that provided SIC codes also provided exposure sources for 338 adults whose lead exposures were determined to be nonoccupational. This group represented 5% of the 6,878 (6,540 occupational plus 338 nonoccupational) adults with BLLs >25 µg/dL. By state, percentages of nonoccupational exposures ranged from >15% in Connecticut, Maine, Maryland, Michigan, and Utah to <1% in Hawaii, Iowa, Montana, Nebraska, and Wisconsin. Among the 338 persons exposed to nonoccupational sources, 23% (78) were exposed from shooting firearms, 19% (65) from remodeling or renovation activities, 13% (45) from hobbies (e.g., casting, ceramics, and stained glass), 11% (36) from retained bullets or gunshot wounds, 7% (26) from pica, and 4% (13) from ingesting lead-contaminated food or liquids or nontraditional medicines. Editorial Note: ABLES data for 2002 indicated that the nationwide rates of elevated BLLs in adults decreased, continuing their decline since 1994 ( Figure 2 ). The decrease in rates could have resulted from improved prevention measures and also changes in employment patterns (e.g., decline in manufacturing jobs). The 2002 ABLES data provide nationwide information on individual adults for the first time; these data are expected to become more complete as reporting states become more experienced with the new individual reporting requirements.
Distribution by State
The findings in this report are subject to at least two limitations. First, inconsistencies exist in the numerators used to calculate the rates. The number of adults with elevated BLLs reported by ABLES states is underreported because 1) not all employers provide BLL testing to all lead-exposed workers and 2) certain laboratories might not report all tests. In addition, these factors can vary among the 35 ABLES states. Second, using the employed population as denominator has the advantage of excluding unemployed adults, most of whom have little or no risk for lead exposure. However, because the distribution of jobs that include lead exposure varies among the ABLES states, caution should be exercised in comparing rates among states. Additional information regarding interpretation of specific state ABLES data is available at http:// www.cdc.gov/niosh/ables.html.
Despite improvements in control of lead exposures, this hazard remains an occupational health problem in the United States. CDC's ABLES program continues to enhance surveillance for this preventable condition by increasing the number of participating states and by identifying the sources of persistent overexposures, helping states focus their intervention, education, and prevention activities. 
Lead Poisoning Associated with Ayurvedic MedicationsFive States, 2000-2003
Although approximately 95% of lead poisoning among U.S. adults results from occupational exposure (1), lead poisoning also can occur from use of traditional or folk remedies (2) (3) (4) (5) . Ayurveda is a traditional form of medicine practiced in India and other South Asian countries. Ayurvedic medications can contain herbs, minerals, metals, or animal products and are made in standardized and nonstandardized formulations (2) . During 2000-2003, a total of 12 cases of lead poisoning among adults in five states associated with ayurvedic medications or remedies were reported to CDC (Table) . This report summarizes these 12 cases. Culturally appropriate educational efforts are needed to inform persons in populations using traditional or folk medications of the potential health risks posed by these remedies.
The first three cases described in this report were reported to CDC by staff at Dartmouth Hitchcock Medical Center at Dartmouth Medical School, New Hampshire; the California Childhood Lead Poisoning Prevention Program; and the California Department of Health Services. To ascertain whether other lead poisoning cases associated with ayurvedic medicines had occurred, an alert was posted on the Epidemic Information Exchange (Epi-X), and findings from the cases in California were posted on the Adult Blood Lead Epidemiology and Surveillance (ABLES) listserv. Nine additional cases were reported by state health departments in Massachusetts, New York, and Texas (Table) .
Case Reports
New Hampshire. A woman aged 37 years with rheumatoid arthritis visited an emergency department (ED) with diffuse abdominal pain, nausea, and vomiting of 6 days' duration. Tests revealed microcytic anemia, moderate basophilic stippling, and no identifiable source of blood loss. Her blood lead level (BLL) was 81 µg/dL (geometric mean BLL = 1.75 µg/dL for U.S. population aged >20 years [6] ), and her zinc protoporphyrin (ZPP) concentration was 286 µg/dL (normal: <35 µg/dL [7] ). She reported ingesting five different traditional medications (two powders and three tablets) obtained from an ayurvedic physician in India for her rheumatoid arthritis. Analysis of the two powders revealed 17,000 and 12,000 parts per million (ppm) lead, respectively, and 60-100 ppm lead in the three tablets. She began oral chelation therapy; 1 week after completion, her BLL was 35 µg/dL. Her two children, aged 6 and 7 years, had BLLs of 5 and 3 µg/dL, respectively. Two years later, the woman reported to her physician with joint symptoms from rheumatoid arthritis and was found to have microcytic anemia and a BLL of 64 µg/dL. She reported restarting ayurvedic medications 2 weeks previously. She agreed to stop taking the medications, and her physician decided against chelation therapy. California. A woman aged 31 years visited an ED with nausea, vomiting, and lower abdominal pain 2 weeks after a spontaneous abortion. One week later, she was hospitalized for severe, persistent microcytic anemia with prominent basophilic stippling that was not improving with iron supplementation. A heavy metals screen revealed a BLL of 112 µg/dL; a repeat BLL 10 days later was 71 µg/dL, before initiation of oral chelation therapy. A ZPP measurement performed at that time was >400 µg/dL. Her husband's BLL was 6 µg/dL. No residential or occupational lead sources were identified, but the woman reported taking nine different ayurvedic medications prescribed by a practitioner in India for fertility during a 2-month period, including one pill four times daily. She discontinued the medications after an abnormal fetal ultrasound 1 month before her initial BLL. Analysis of her medications revealed 73,900 ppm lead in the pill taken four times daily and 21, 65, and 285 ppm lead in three other remedies. Her BLL was 22 µg/dL when she was tested 9.5 months after the initial BLL testing.
A man aged 34 years was evaluated twice in an ED for back pain and abdominal pain. A screen for heavy metals revealed a BLL of 80 µg/dL. He was hospitalized for chelation therapy and disclosed that he had been taking ayurvedic medications prescribed by a practitioner in India to increase fertility. He had discontinued use the previous day. The 10 preparations included pills, powders, and syrups, most of which were not labeled. He had taken one type of tablet once daily for 3 months; samples of one of these tablets contained 78,000 ppm lead. A second variety of pill contained 36 ppm lead. A home investigation revealed no other sources of lead. His BLL was 17 µg/dL when tested 7.5 months after the initial BLL test.
Massachusetts, New York, and Texas. Nine additional cases were reported from Massachusetts, New York, and Texas (Table) . The median age of patients was 52 years; five patients were female. The five women were taking the medications for arthritis (one), menstrual health (one), and diabetes (three). The four men were taking the medications for arthritis (one) and diabetes (three). (3) . In this report, the majority of persons affected were of Asian Indian or other East Indian descent. Several ayurvedic and other traditional medications do not contain lead; however, lead content has ranged from 0.4 to 261,200 ppm in certain common ayurvedic preparations (8) . Certain branches of ayurvedic medicine consider heavy metals to be therapeutic and encourage their use in the treatment of certain ailments.
Symptoms of lead toxicity in adults often vary and are nonspecific; these include abdominal pain, fatigue, decreased libido, headache, irritability, arthralgias, myalgias, and neurologic dysfunction ranging from subtle neurocognitive deficits to a predominantly motor peripheral neuropathy to encephalopathy (9) . The number and severity of symptoms typically increase as BLLs increase; however, the toxic effects of lead can occur without overt symptoms. In assessing patients with nonspecific, multisystemic symptoms, medical and public health professionals should consider lead toxicity in the differential diagnosis and request BLL testing. The finding of a high BLL without an obvious occupational or environmental source should elicit inquiries about traditional or folk medications as a potential source of exposure. Primary management of lead toxicity is source identification and exposure cessation. In adults, chelation therapy usually is reserved for patients with substantial symptoms or signs of lead toxicity or BLLs of >80 µg/dL (9) .
Culturally appropriate educational efforts are needed to inform persons of the potential health risks posed by these remedies, particularly in populations in which traditional or folk medication use is prevalent. For remedies known to contain lead or to be possibly adulterated with lead, educational materials should state the potential health effects. Young children and fetuses of pregnant women are at added risk for the toxic effects of lead, particularly because of the use of these products to treat infertility in women (10) .
Identification of the additional nine cases underscores the value of electronic health communications systems, such as listservs and Epi-X. These systems disseminate information quickly for geographically dispersed events that could be missed by routine surveillance systems.
Childhood Lead Poisoning from
Commercially Manufactured French Ceramic DinnerwareNew York City, 2003
Lead poisoning adversely affects children worldwide. During 1999-2000, an estimated 434,000 children aged 1-5 years in the United States had elevated blood lead levels (BLLs) >10 µg/dL (1). Glazes found on ceramics, earthenware, bone china, and porcelain often contain lead and are a potential source of lead exposure. Children are especially vulnerable to the neurotoxic effects of lead. Exposures to lead in early childhood can have adverse effects on the developing nervous system, resulting in decreased intelligence and changes in behavior (1) . In addition, certain behaviors (e.g., thumb sucking) place children at greater risk for exposure to lead. In 2003, the New York City Department of Health and Mental Hygiene's Lead Poisoning Prevention Program (LPPP), and the Mount Sinai Pediatric Environmental Health Specialty Unit (PEHSU) investigated a case of lead poisoning in a boy aged 20 months. This report summarizes that case investigation, which identified ceramic dinnerware imported from France as the source of lead exposure. This case underscores the susceptibility of children to a toxic exposure associated with 1) the high proportion of time spent in the home and 2) dietary habits that promote exposure to lead leached from ceramic ware.
In July 2002, the patient's lead exposure was first identified when a routine lead screening at age 12 months revealed a BLL of 15 µg/dL, which exceeds CDC's level of concern (>10 µg/dL). Follow-up at age 15 months documented a BLL of 18 µg/dL. The child's pediatrician provided guidance to the child's parents on lead hazards. A private environmental testing company confirmed the absence of lead-based paint in the family's home by using x-ray fluorescence. However, at age 18 months, the child's BLL increased to 23 µg/dL. In February 2003, LPPP completed a comprehensive investigation of the child's home and assessed the child's routine daily activities and physical environment and found no lead paint hazards, although concern was raised by an LPPP investigator about the ceramic dinnerware used regularly by the child. A home lead test (2) was conducted by the family and revealed that the ceramic dinnerware was positive for lead.
In March 2003, the child was referred to Mount Sinai PEHSU for a secondary evaluation. A plate from the dinnerware also was submitted for evaluation, and PEHSU requested assistance from the Food and Drug Administration (FDA) to test the plate. The sample plate appeared to be in good condition and had no visible cracks or signs of wear. The plate was tested for lead by using an FDA protocol, whereby lead is extracted from the food contact surface (3) (4) (5) . In accordance with this standard protocol, the plate was leached in a 4% acetic acid solution for 24 hours at a temperature of 71.6 º F (22.2 º C). The amount of lead released was measured by flame atomic absorption spectroscopy. The ceramic plate released 29.6 µg/mL of lead into the leaching solution, a level exceeding the FDA compliance guideline of <3 µg/mL.
The child was home full time and consumed all meals and beverages using the dinnerware. Because of concerns about lead exposure to other family members, BLLs of the child's mother and grandmother also were assessed. Results for both were <5 µg/dL, substantially lower than the child's BLLs. The family was advised to discontinue use of the dinnerware. On follow-up at age 23 months, the child's BLL had decreased to 8 µg/dL.
The particular brand of dinnerware identified in this investigation is no longer sold in the United States. However, plates of this brand are available online and might still be available for sale in discount stores, flea markets, and online auctions. Additional tests will be conducted on plates from the same manufacturer to determine the extent of the problem. A complete listing of dinnerware that has been restricted for importation into the United States is available at http://www.fda.gov/ ora/fiars/ora_import_ia5208.html. Editorial Note: When investigating lead poisonings, examining the most common sources of lead exposure (e.g., occupational exposures or lead-based paint) is a critical first step; after these sources are ruled out, other sources should be investigated. Traditionally, more concern has been raised about the presence of lead glazes in homemade ceramics than in manufactured dinnerware. The case described in this report illustrates how imported, commercially manufactured dinnerware also should be considered as potential sources of lead exposure.
Lead can leach out of ceramic ware when the glaze is improperly fired or when the glaze has broken down because of wear from daily usage, particularly after repeated use in a microwave or dishwasher (6) . Chips and cracks in ceramic ware also allow leaching of lead. When lead is released into food and drink from ceramics, hazardous levels can contaminate food substances and expose children and adults to toxic levels. Children's risk for such exposures is compounded by their diets, especially their frequent consumption of acidic juices (e.g., orange and apple juices) that promote leaching of lead from ceramics. 
West Nile Virus Activity -United States, June 30-July 6, 2004
During June 30-July 6, a total of 21 human cases of West Nile virus (WNV) illness were reported from two states (Arizona and California). During 2004, eight states have reported a total of 78 human cases of WNV illness to CDC through ArboNET (Table, Figure) . Of these, 57 (73%) were reported from Arizona. Forty-seven (61%) of the 78 cases occurred in males; the median age of patients was 53 years (range: 1-84 years); the dates of illness onset ranged from April 23 to June 28; and one case was fatal.
A total of 20 presumptive West Nile viremic blood donors (PVDs) have been reported to ArboNET. Of these, 19 were reported from Arizona, and one was reported from New Mexico. Of the 20 PVDs reported to ArboNET, one person aged 69 years subsequently had neuroinvasive illness, and four persons aged 22, 51, 52, and 57 years subsequently had West Nile fever. In New Mexico, the first reported human WNV infection in 2004 was in a PVD; in Arizona, three of the first seven reported human WNV infections of 2004 were in PVDs.
In addition, during 2004, a total of 861 dead corvids and 86 other dead birds with WNV infection have been reported from 24 states, and 42 WNV infections in horses have been reported from 11 states (Alabama, Arizona, California, Idaho, Missouri, North Carolina, Oklahoma, South Dakota, Tennessee, Texas, and Virginia). WNV seroconversions have been reported in 110 sentinel chicken flocks from four states (Arizona, California, Florida, and Louisiana). Three seropositive sentinel horses were reported from Puerto Rico. A total of 226 WNV-positive mosquito pools have been reported from 12 states (Arizona, California, Illinois, Indiana, Louisiana, Michigan, Missouri, New Jersey, Ohio, Pennsylvania, Texas, and Virginia).
Additional information about national WNV activity is available from CDC at http://www.cdc.gov/ncidod/dvbid/ westnile/index.htm and at http://westnilemaps.usgs.gov. 
Investigation of Rabies Infections in
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donor, who was found subsequently to have serologic evidence of rabies infection. The transplant recipients had encephalitis of unknown etiology after transplantation and subsequently died. Specimens were sent to CDC for diagnostic evaluation. This report provides a brief summary of the ongoing investigation and information on exposure risks and postexposure measures.
Organ Donor
The organ donor was an Arkansas man who visited two hospitals in Texas with severe mental status changes and a low-grade fever. Neurologic imaging indicated findings consistent with a subarachnoid hemorrhage, which expanded rapidly in the 48 hours after admission, leading to cerebral herniation and death. Donor eligibility screening and testing did not reveal any contraindications to transplantation, and the patient's family agreed to organ donation. Lungs, kidneys, and liver were recovered. No other organs or tissues were recovered from the donor, and the donor did not receive any blood products before death. The liver and kidneys were transplanted into three recipients on May 4 at a transplant center in Texas. The lungs were transplanted in an Alabama hospital into a patient who died of intraoperative complications.
Liver Recipient
The liver recipient was a man with end-stage liver disease. The patient did well immediately after transplantation and was discharged home on postoperative day 5. Twenty-one days after transplant, the patient was readmitted with tremors, lethargy, and anorexia; he was afebrile. The patient's neurologic status deteriorated rapidly during the next 24 hours; he required intubation and critical care support. A lumbar puncture indicated a mild lymphocytic pleocytosis (25 white blood cells/mm 3 ) and a mildly elevated protein. Magnetic resonance imaging (MRI) of the brain indicated increased signal in the cerebrospinal fluid. His neurologic status continued to deteriorate. Six days after admission, a repeat MRI indicated diffuse encephalitis. The patient subsequently died.
Female Kidney Recipient
The first kidney recipient was a woman with end-stage renal disease caused by hypertension and diabetes. She had no postoperative complications and was discharged home on postoperative day 7. Twenty-five days after transplant, she was readmitted with right-side flank pain and underwent an appendectomy. Two days after this procedure, she had diffuse twitching and was noted to be increasingly lethargic. Neurologic imaging with computed tomography and MRI indicated no abnormality. During the next 24-48 hours, the patient had worsening mental status, seizures, hypotension, and respiratory failure requiring intubation. Her mental status continued to deteriorate, and cerebral imaging 2 weeks after admission indicated severe cerebral edema. The patient subsequently died.
Male Kidney Recipient
The second renal recipient was a man with end-stage renal disease caused by focal, segmental glomerulosclerosis. His posttransplant course was complicated briefly by occlusions of an arterial graft leading to infarction of the lower pole of the transplanted kidney. The patient was discharged home 12 days after transplantation. Twenty-seven days after transplantation, he visited a hospital emergency department and was then transferred to the transplant center with myoclonic jerks and altered mental status; he was afebrile. An MRI of the brain performed on admission revealed no abnormalities. His mental status deteriorated rapidly during the next 24 hours. A lumbar puncture revealed mild lymphocytic pleocytosis (16 white blood cells/mm 3 ) and a mildly elevated protein. His mental status continued to deteriorate, leading to respiratory failure requiring intubation. A repeat MRI performed 10 days after admission indicated diffuse edema. The patient subsequently died.
Laboratory Investigation
In all three patients, histopathologic examination of central nervous system (CNS) tissues at CDC revealed an encephalitis with viral inclusions suggestive of Negri bodies; the diagnosis of rabies in all three recipients was confirmed by immunohistochemical testing and by the detection of rabies virus antigen in fixed brain tissue by direct fluorescent antibody tests (Figure 1 ). Electron microscopy of CNS tissue of one of the renal transplant recipients also identified characteristic rhabdovirus inclusions and viral particles (Figure 2) . Suckling mice inoculated intracranially and intraperitoneally with brain tissue from one kidney recipient died 7-9 days after injection. Thin-section electron microscopy of CNS tissue of the mice had visible rhabdovirus particles, and immunohistochemical testing detected rabies viral antigens. Antigenic typing performed upon brain tissue from one recipient was compatible with a rabies virus variant associated with bats. Rabies virus antibodies were demonstrated in blood from two of the three recipients and the donor. Detecting rabies antibodies in the donor suggests that he was the likely source of rabies transmission to the organ recipients. Testing of additional donor specimens is ongoing.
Editorial Note: Rabies is an acute fatal encephalitis caused by neurotropic viruses in the genus Lyssavirus, family Rhabdoviridae (1). The majority of rabies cases are caused by bites by rabid mammals (1, 2) . Nonbite exposures, including scratches, contamination of an open wound, or direct mucous membrane contact with infectious material (e.g., saliva or neuronal tissue from rabid animals), rarely cause rabies. After an incubation period of several weeks to months, the virus passes via the peripheral nervous system and replicates in the central nervous system. Rabies virus can then be disseminated to salivary glands and other organs via neural innervation (3) . Rabies can be prevented by administration of rabies postexposure prophylaxis (PEP) (4), which is highly effective in preventing rabies when administered before onset of clinical signs.
Although transmission of rabies has occurred previously among eight recipients of transplanted corneas in five countries (4), this report describes the first documented cases of rabies virus transmission among solid organ transplant recipients. Infection with rabies virus likely occurred via neuronal tissue contained in the transplanted organs, as rabies virus is not spread hematologically. In collaboration with CDC, state and local health departments in Alabama, Arkansas, Oklahoma, and Texas have initiated investigations to identify a potential source of exposure for the donor and to identify contacts of patients among health-care providers or domestic contacts who might need rabies PEP.
The risk for health-care-associated transmission of rabies is extremely low; transmission of rabies virus from infected patients to health-care providers has not been documented (5) . The use of Standard Precautions (6) for contact with blood and body fluids (e.g., gloves, gown, mask, goggles, or face shield as indicated for the type of patient contact) prevents exposure to the rabies virus. No laboratory-confirmed cases of human-to-human transmission of rabies among household contacts have been reported (4) . No cases of rabies have been reported in association with transmission by fomites or environmental surfaces.
Routes of possible exposure include percutaneous and mucocutaneous entry of the rabies virus through a wound, nonintact skin, or mucous membrane contact. Intact skin contact with infectious materials is not considered an exposure to the rabies virus. Persons with exposure as defined above to saliva, nerve tissue, or cerebral spinal fluid from any of the four infected patients should receive rabies PEP. Types of exposures in domestic settings for which administration of PEP would be appropriate include bites, sexual activity, exchanging kisses on the mouth or other direct mucous membrane contact with saliva, and sharing eating or drinking utensils or cigarettes. In health-care settings, additional 
CDC Photo
opportunities that can lead to contamination of mucous membranes or nonintact skin with oral secretions include procedures such as intubation or suctioning of respiratory secretions or injuries with sharp instruments (e.g., needlesticks or scalpel cuts). Percutaneous injuries (e.g., needlesticks) are considered exposures because of potential contact with nervous tissue. Contact with patient fluids (e.g., blood, urine, or feces) does not pose a risk for rabies exposure (4) .
All potential organ donors in the United States are screened and tested to identify if the donor might present an infectious risk. Organ procurement organizations are responsible for evaluating organ donor suitability, consistent with minimum procurement standards (7) . Donor eligibility is determined through a series of questions posed to family and contacts, physical examination, and blood testing for evidence of organ dysfunction and selected bloodborne viral pathogens and syphilis. Laboratory testing for rabies is not performed. In the case reported here, the donor's death was attributed to noninfectious causes. The role of organ donor deferral is to optimize successful transplantation in the recipient, including minimizing risk of infectious disease transmission to the lowest level reasonably achievable without unduly decreasing the availability of this life-saving resource. The benefits from transplanted organs outweigh the risk for transmission of infectious diseases from screened donors. CDC is working with federal and organ procurement agencies to review donor screening practices.
Additional information about rabies and its prevention is available from CDC, telephone 404-639-1050, or at http:// www.cdc.gov/ncidod/dvrd/rabies. Additional information about organ transplantation is available at http://www.optn. org/about/donation.
Notice to Readers
Updated Recommendations for Use of Pneumococcal Conjugate Vaccine: Reinstatement of the Third Dose
In February 2004, production of the 7-valent pneumococcal conjugate vaccine (PCV7), marketed as Prevnar ® and manufactured by Wyeth Vaccines (Collegeville, Pennsylvania), failed to meet demand, resulting in shortages. To conserve the limited supply, CDC recommended that the fourth dose of PCV7 be withheld from healthy children (1). In March, because evidence indicated that production would be curtailed for several months, CDC recommended that the third dose also be withheld (2) . Production problems now appear to have been resolved. As a result, deliveries are projected during the near term to permit the recommendation that every child receive 3 doses. Some providers might have short-term difficulties obtaining vaccine because of distribution delays; however, every effort will be made to provide sufficient vaccine to all providers.
Effective immediately, CDC, in consultation with the Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians, and the American Academy of Pediatrics, recommends that providers administer 3 doses of vaccine (3). The fourth dose should still be deferred for healthy children until further production and supply data demonstrate that a 4-dose schedule can be sustained. The full, 4-dose series should continue to be administered to children at increased risk for pneumococcal disease because of certain immunocompromising or chronic conditions (e.g., sickle cell disease, anatomic asplenia, chronic heart or lung disease, diabetes, cerebrospinal fluid leak, and cochlear implant [4] ). Alaska Native children and American Indian children who live in Alaska, Arizona, or New Mexico, and Navajo children who live in Colorado and Utah have a risk for invasive pneumococcal disease more than twice the national average. These children should receive the standard 4-dose PCV7 series despite the shortage.
An interim catch-up schedule is provided for children who are incompletely vaccinated (Table) . The highest priority for catch-up vaccination is to ensure that children aged <5 years at high risk for invasive pneumococcal disease are fully vaccinated. Second priorities include vaccination of healthy children aged <24 months who have not received any doses of PCV7 and vaccination of healthy children aged <12 months who have not yet received 3 doses.
Because of the frequency of health-care provider visits by children during their first 18 months, catch-up vaccination might occur at regularly scheduled visits for most children who receive vaccines from their primary-care providers. Programs that provide vaccinations but do not see children routinely for other reasons should consider a notification process to contact undervaccinated children.
Wyeth Vaccines is allocating nonpublic-purchased doses of Prevnar ® directly to all physicians on the basis of previous purchasing patterns or practice birth cohort. Wyeth does not currently ship products to either wholesalers or distributors. Providers with questions about their allocation or about obtaining Prevnar ® should contact Wyeth's customer service department, telephone 800-666-7428. For problems not resolved by the customer service department, providers can contact Wyeth directly, telephone 866-447-8888, extension 37932. For public-purchased vaccine, including Vaccines for Children Program vaccine, providers should contact their state/ grantee immunization projects to obtain vaccine. These projects should contact their project officers at the National Immunization Program at CDC for information regarding vaccine supply.
This recommendation reflects CDC's assessment of the existing national PCV7 supply and will be changed if the supply changes. Updated information about the national PCV7 supply is available from CDC at http://www.cdc.gov/nip/ news/shortages/default.htm.
Notice to Readers
Availability of Revised Guidelines for Identifying and Managing Jaundice in Newborns
The American Academy of Pediatrics has published revised guidelines for identifying and managing jaundice in newborns. Jaundice is caused by an increase in serum bilirubin concentration (i.e., hyperbilirubemia) (1) and makes the skin appear yellow. Excessive hyperbilirubinemia can lead to permanent brain damage (i.e., kernicterus) (1). The revised guidelines were developed to promote greater uniformity and consistency of care for all newborns. Four key recommendations were emphasized for physicians:
• Perform a systematic assessment of all infants before their discharge from the birth hospital. This assessment will determine their risk for severe jaundice and can be 1 dose, 2 mos after the most recent dose 7-11 0 doses 2 doses, 2 mos apart; third dose at age 12-15 mos 1 dose before age 7 mos 1 dose at age 7-11 mos, with another dose at age 12-15 mos (>2 mos later) 2 doses before age 7 mos 1 dose at age 7-11 mos 12-23 0 doses 2 doses, >2 mos apart 1 dose before age 12 mos 2 doses, >2 mos apart 1 dose at age >12 mos 1 dose, >2 mos after the most recent dose 2 doses at age <12 mos 1 dose, >2 mos after the most recent dose 24-59
Healthy children Not routinely recommended † Children at high risk § Any incomplete schedule of <3 doses 1 dose, >2 mos after the most recent dose and another dose >2 mos later Any incomplete schedule of 3 doses 1 dose, >2 mos after the most recent dose * For children vaccinated at age <12 months, the minimum interval between doses is 4 weeks. Doses administered at age >12 months should be >8 weeks apart. † When the shortage is resolved completely, health-care providers should consider administering a single dose to unvaccinated, healthy children aged 24-59 months (with priority given to children aged 24-35 months), black children, American Indian children not otherwise identified as high risk § , and children who attend day care centers. § Children with sickle cell disease, asplenia, chronic heart or lung disease, diabetes, cerebrospinal fluid leak, cochlear implant, human immunodeficiency virus infection or another immunocompromising condition, and Alaska Native or American Indian children in areas with demonstrated risk for invasive pneumococcal disease more than twice the national average (i.e., Alaska, Arizona, New Mexico, and Navajo populations in Colorado and Utah).
Please note: An erratum has been published for this issue. To view the erratum, please click here.
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performed by measuring the total serum bilirubin or transcutaneous bilirubin levels, or assessing risk factors, or both (2 
